NCL diseases - clinical perspectives

被引:175
作者
Schulz, Angela [1 ]
Kohlschuetter, Alfried [1 ]
Mink, Jonathan [2 ]
Simonati, Alessandro [3 ]
Williams, Ruth [4 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Childrens Hosp, Hamburg, Germany
[2] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA
[3] Univ Verona, Dept Child Neurol, I-37100 Verona, Italy
[4] Guys & St Thomas NHS Fdn Trust, Dept Childrens Neurosci, London, England
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2013年 / 1832卷 / 11期
关键词
Batten; Ceroid; NCLs; Disease classification; Diagnostic algorithm; NEURONAL CEROID-LIPOFUSCINOSIS; CLN1; MUTATION; KUFS-DISEASE; DEFICIENCY; FORM;
D O I
10.1016/j.bbadis.2013.04.008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The neuronal ceroid lipofuscinoses (NCLs) are lysosomal storage disorders and together are the most common degenerative brain diseases in childhood. They are a group of disorders linked by the characteristic accumulation of abnormal storage material in neurons and other cell types, and a degenerative disease course. All NCLs are characterized by a combination of dementia, epilepsy, and motor decline. For most childhood NCLs, a progressive visual failure is also a core feature. The characteristics of these symptoms can vary and the age at disease onset ranges from birth to young adulthood. Genetic heterogeneity, with fourteen identified NCL genes and wide phenotypic variability render diagnosis difficult. A new NCL classification system based on the affected gene and the age at disease onset allows a precise and practical delineation of an individual patient's NCL type. A diagnostic algorithm to identify each NCL form is presented here. Precise NCL diagnosis is essential not only for genetic counseling, but also for the optimal delivery of care and information sharing with the family and other caregivers. These aspects are challenging because there are also potential long term complications which are specific to NCL type. Therefore care supported by a specifically experienced team of clinicians is recommended. As the underlying pathophysiological mechanism is still unclear for all NCL forms, the development of curative therapies remains difficult. This article is part of a Special Issue entitled: The neuronal ceroid lipofuscinoses or Batten Disease. (C) 2013 Published by Elsevier B.V.
引用
收藏
页码:1801 / 1806
页数:6
相关论文
共 29 条
[1]  
Aberg L., 2011, NEURONAL CEROID LIPO, P110
[2]  
Aiello C., 2011, NEURONAL CEROID LIPO, P189
[3]  
Alroy J., 2011, NEURONAL CEROID LIPO, P159, DOI DOI 10.1093/MED/9780199590018.003.0010
[4]   Kufs Disease, the Major Adult Form of Neuronal Ceroid Lipofuscinosis, Caused by Mutations in CLN6 [J].
Arsov, Todor ;
Smith, Katherine R. ;
Damiano, John ;
Franceschetti, Silvana ;
Canafoglia, Laura ;
Bromhead, Catherine J. ;
Andermann, Eva ;
Vears, Danya F. ;
Cossette, Patrick ;
Rajagopalan, Sulekha ;
McDougall, Alan ;
Sofia, Vito ;
Farrell, Michael ;
Aguglia, Umberto ;
Zini, Andrea ;
Meletti, Stefano ;
Morbin, Michela ;
Mullen, Saul ;
Andermann, Frederick ;
Mole, Sara E. ;
Bahlo, Melanie ;
Berkovic, Samuel F. .
AMERICAN JOURNAL OF HUMAN GENETICS, 2011, 88 (05) :566-573
[5]  
Autti T., 2011, NEURONAL CEROID LIPO, P55
[6]  
Berkovic S F, 1988, Am J Med Genet Suppl, V5, P105
[7]   Novel CLN1 mutation in two Italian sibs with late infantile neuronal ceroid lipofuscinosis [J].
Bonsignore, Maria ;
Tessa, Alessandra ;
Di Rosa, Gabriella ;
Piemonte, Fiorella ;
Dionisi-Vici, Carlo ;
Simonati, Alessandro ;
Calamoneri, Filippo ;
Tortorella, Gaetano ;
Santorelli, Filippo M. .
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2006, 10 (03) :154-156
[8]  
Bras J., 2012, HUM MOL GENET, V21, P4240
[9]  
Chang M., 2011, The Neuronal Ceroid Lipofuscinoses (Batten Disease), P80
[10]  
Elleder M., 2011, NEURONAL CEROID LIPO, V2nd, P176